AI Engines For more Details: Perplexity Kagi Labs You
Prostate Cancer: Nilutamide is classified as an antiandrogen medication and is used in combination with other treatments (such as surgical castration or luteinizing hormone-releasing hormone agonists) for the treatment of metastatic prostate cancer in men. It works by blocking the effects of androgens (male hormones) on the prostate cancer cells, thereby slowing down the growth and spread of the cancer.
Androgen Blockade: Nilutamide competitively inhibits the binding of androgens (such as testosterone) to androgen receptors in prostate cancer cells. By blocking the androgen receptors, nilutamide interferes with the signaling pathways that promote the growth and survival of prostate cancer cells. This antiandrogenic effect helps to suppress the progression of prostate cancer and may lead to a reduction in tumor size and serum prostate-specific antigen (PSA) levels.
Metastatic Disease: Nilutamide is particularly beneficial in the treatment of metastatic prostate cancer, where the cancer has spread beyond the prostate gland to other parts of the body, such as the bones, lymph nodes, or distant organs. By inhibiting the growth of cancer cells and reducing the production of PSA, nilutamide may help slow down disease progression and improve survival outcomes in men with metastatic prostate cancer.
Symptom Relief: In addition to its anticancer effects, nilutamide may also provide symptom relief in men with advanced prostate cancer. By reducing the size of the prostate tumor and alleviating pressure on surrounding tissues and organs, nilutamide can help alleviate symptoms such as urinary obstruction, bone pain, and other complications associated with advanced prostate cancer.
Side Effects: Common side effects of nilutamide may include hot flashes, decreased libido, erectile dysfunction, breast tenderness or enlargement (gynecomastia), nausea, vomiting, diarrhea, fatigue, and liver function abnormalities. Serious adverse effects such as hepatotoxicity (liver damage), interstitial pneumonitis, and visual disturbances (including impaired dark adaptation and night blindness) are rare but may occur with prolonged use of nilutamide.
Monitoring: Patients receiving nilutamide therapy require regular monitoring of liver function tests (LFTs), serum PSA levels, and ocular examinations to detect and manage any potential adverse effects or complications associated with treatment. Dosage adjustments or discontinuation of nilutamide may be necessary in cases of severe adverse reactions or hepatic dysfunction.
Contraindications: Nilutamide is contraindicated in individuals with a history of hypersensitivity or allergic reactions to the medication, as well as in pregnant women or women of childbearing potential due to the risk of fetal harm. It should be used with caution in patients with preexisting liver disease or impairment.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Bacteroides uniformis | Reduces |
| species | Bifidobacterium adolescentis | Reduces |
| species | Bifidobacterium longum | Reduces |
| species | Escherichia coli | Reduces |
| species | Parabacteroides distasonis | Reduces |
| subspecies | Bifidobacterium longum subsp. infantis | Reduces |
| subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.8 | 0.8 | |
| Acne | 0.6 | 0.9 | -0.5 |
| ADHD | 4.9 | 0.9 | 4.44 |
| Age-Related Macular Degeneration and Glaucoma | 1.1 | 0.4 | 1.75 |
| Allergic Rhinitis (Hay Fever) | 3.1 | 2.3 | 0.35 |
| Allergies | 7.5 | 3.7 | 1.03 |
| Allergy to milk products | 2 | 1.6 | 0.25 |
| Alopecia (Hair Loss) | 1.3 | 1.3 | |
| Alzheimer's disease | 7 | 7.8 | -0.11 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 4 | 1.5 | 1.67 |
| Ankylosing spondylitis | 4 | 1.2 | 2.33 |
| Anorexia Nervosa | 1.6 | 3.1 | -0.94 |
| Antiphospholipid syndrome (APS) | 1.9 | 0.3 | 5.33 |
| Asthma | 5.4 | 2.3 | 1.35 |
| Atherosclerosis | 2.6 | 2.7 | -0.04 |
| Atrial fibrillation | 3.9 | 2.4 | 0.63 |
| Autism | 9.9 | 9.2 | 0.08 |
| Autoimmune Disease | 1.2 | 1 | 0.2 |
| Barrett esophagus cancer | 0.6 | 0.3 | 1 |
| benign prostatic hyperplasia | 0.6 | 0.3 | 1 |
| Biofilm | 2.1 | 2.1 | |
| Bipolar Disorder | 2.4 | 1.7 | 0.41 |
| Brain Trauma | 0.9 | 1.4 | -0.56 |
| Breast Cancer | 1.8 | 0.3 | 5 |
| Cancer (General) | 0.9 | 2.2 | -1.44 |
| Carcinoma | 5.2 | 2.6 | 1 |
| Celiac Disease | 3.3 | 3.2 | 0.03 |
| Cerebral Palsy | 1.4 | 1.3 | 0.08 |
| Chronic Fatigue Syndrome | 5.9 | 7 | -0.19 |
| Chronic Kidney Disease | 4.6 | 2.8 | 0.64 |
| Chronic Lyme | 0.7 | 0.8 | -0.14 |
| Chronic Obstructive Pulmonary Disease (COPD) | 2.4 | 2 | 0.2 |
| Chronic Urticaria (Hives) | 2 | 0.4 | 4 |
| Coagulation / Micro clot triggering bacteria | 2 | 1.3 | 0.54 |
| Cognitive Function | 4.1 | 1.6 | 1.56 |
| Colorectal Cancer | 8.9 | 3.1 | 1.87 |
| Constipation | 2.7 | 1.6 | 0.69 |
| Coronary artery disease | 2.4 | 2.8 | -0.17 |
| COVID-19 | 10.7 | 12.1 | -0.13 |
| Crohn's Disease | 8.8 | 5.6 | 0.57 |
| Cushing's Syndrome (hypercortisolism) | 0.9 | -0.9 | |
| cystic fibrosis | 1.2 | 1.9 | -0.58 |
| d-lactic acidosis (one form of brain fog) | 0.7 | 0.7 | |
| deep vein thrombosis | 3.5 | 1.4 | 1.5 |
| Denture Wearers Oral Shifts | 1.7 | 1.7 | |
| Depression | 11 | 8.2 | 0.34 |
| Dermatomyositis | 0.3 | 0.3 | 0 |
| Eczema | 1.7 | 2.6 | -0.53 |
| Endometriosis | 3.5 | 2.7 | 0.3 |
| Eosinophilic Esophagitis | 0.3 | 0.6 | -1 |
| Epilepsy | 3.9 | 1.7 | 1.29 |
| erectile dysfunction | 1.9 | 0.3 | 5.33 |
| Fibromyalgia | 3.5 | 2.7 | 0.3 |
| Functional constipation / chronic idiopathic constipation | 6.1 | 4.1 | 0.49 |
| gallstone disease (gsd) | 3.6 | 1.1 | 2.27 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 2.2 | 1.2 | 0.83 |
| Generalized anxiety disorder | 2.8 | 2 | 0.4 |
| giant cell arteritis | 0.2 | -0.2 | |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 2.3 | 1.4 | 0.64 |
| Graves' disease | 1.9 | 3.3 | -0.74 |
| Gulf War Syndrome | 0.9 | 1.3 | -0.44 |
| Halitosis | 1.7 | 0.3 | 4.67 |
| Hashimoto's thyroiditis | 3.8 | 1.8 | 1.11 |
| Heart Failure | 4.9 | 2.7 | 0.81 |
| hemorrhagic stroke | 1.3 | 1.3 | |
| Hidradenitis Suppurativa | 1.4 | 0.3 | 3.67 |
| High Histamine/low DAO | 2 | 0.6 | 2.33 |
| hypercholesterolemia (High Cholesterol) | 1.1 | 1.1 | |
| hyperglycemia | 2.1 | 1.1 | 0.91 |
| Hyperlipidemia (High Blood Fats) | 0.9 | 0.3 | 2 |
| hypersomnia | 0.7 | -0.7 | |
| hypertension (High Blood Pressure | 4.6 | 5.6 | -0.22 |
| Hypothyroidism | 0.9 | 1 | -0.11 |
| Hypoxia | 3.6 | 0.3 | 11 |
| IgA nephropathy (IgAN) | 1.9 | 4.3 | -1.26 |
| Inflammatory Bowel Disease | 9.8 | 9.2 | 0.07 |
| Insomnia | 2.4 | 2.4 | 0 |
| Intelligence | 2.6 | 2.6 | |
| Intracranial aneurysms | 1.4 | 0.9 | 0.56 |
| Irritable Bowel Syndrome | 8.1 | 5.3 | 0.53 |
| ischemic stroke | 2.7 | 1.7 | 0.59 |
| Liver Cirrhosis | 8.2 | 4.3 | 0.91 |
| Long COVID | 7.2 | 8.3 | -0.15 |
| Low bone mineral density | 1.1 | -1.1 | |
| Lung Cancer | 1.5 | 1 | 0.5 |
| Lymphoma | 0.9 | 0.9 | |
| Mast Cell Issues / mastitis | 1.4 | 0.9 | 0.56 |
| ME/CFS with IBS | 1 | 2.2 | -1.2 |
| ME/CFS without IBS | 1.3 | 2.1 | -0.62 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 1.6 | 0.5 | 2.2 |
| Metabolic Syndrome | 8.2 | 7.8 | 0.05 |
| Mood Disorders | 10.3 | 6.9 | 0.49 |
| multiple chemical sensitivity [MCS] | 0.8 | 0.1 | 7 |
| Multiple Sclerosis | 7.2 | 5.9 | 0.22 |
| Multiple system atrophy (MSA) | 1 | 0.7 | 0.43 |
| myasthenia gravis | 0.9 | 0.7 | 0.29 |
| neuropathic pain | 0.3 | 3.1 | -9.33 |
| Neuropathy (all types) | 0.7 | 3.1 | -3.43 |
| neuropsychiatric disorders (PANDAS, PANS) | 1.2 | 1.2 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 5.8 | 4.2 | 0.38 |
| NonCeliac Gluten Sensitivity | 1.3 | 0.6 | 1.17 |
| Obesity | 10.3 | 7.1 | 0.45 |
| obsessive-compulsive disorder | 7 | 3 | 1.33 |
| Osteoarthritis | 2.6 | 1.2 | 1.17 |
| Osteoporosis | 3.1 | 1.6 | 0.94 |
| pancreatic cancer | 2.3 | 0.6 | 2.83 |
| Parkinson's Disease | 8.6 | 7.3 | 0.18 |
| Polycystic ovary syndrome | 6.8 | 3.3 | 1.06 |
| Postural orthostatic tachycardia syndrome | 0.2 | 0.6 | -2 |
| Premenstrual dysphoric disorder | 0.7 | 0.4 | 0.75 |
| primary biliary cholangitis | 1.2 | 1.7 | -0.42 |
| Primary sclerosing cholangitis | 2.8 | 2.3 | 0.22 |
| Psoriasis | 3.8 | 2.4 | 0.58 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 7.3 | 4.5 | 0.62 |
| Rosacea | 1.2 | 1 | 0.2 |
| Schizophrenia | 7.3 | 3.1 | 1.35 |
| scoliosis | 0.9 | 1.2 | -0.33 |
| Sjögren syndrome | 2.6 | 3.2 | -0.23 |
| Sleep Apnea | 2.2 | 1.8 | 0.22 |
| Slow gastric motility / Gastroparesis | 1.5 | 0.3 | 4 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 2.3 | 0.1 | 22 |
| Stress / posttraumatic stress disorder | 3.3 | 2.7 | 0.22 |
| Systemic Lupus Erythematosus | 4.1 | 1.9 | 1.16 |
| Tic Disorder | 1.5 | 1.2 | 0.25 |
| Tourette syndrome | 0.9 | 0.3 | 2 |
| Type 1 Diabetes | 5.2 | 3.8 | 0.37 |
| Type 2 Diabetes | 9.1 | 8.3 | 0.1 |
| Ulcerative colitis | 7.3 | 7.5 | -0.03 |
| Unhealthy Ageing | 5.9 | 2.4 | 1.46 |
| Vitiligo | 2.3 | 1.3 | 0.77 |
